MYOS Corp (Form: 8-K, Received: 05/21/2012 16:42:12)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 21, 2012 (May 15, 2012)

(Exact name of registrant as specified in its charter)

Nevada		000-53298		20-8758875
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

45 Horsehill Road, Suite 106

Cedar Knolls, New Jersey 07927

(Address of Principal Executive Offices)

(973) 509-0444

(Issuer’s telephone number)

Atlas Therapeutics Corporation

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.03 Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year.

On May 15, 2012, Atlas Therapeutics Corporation (the “ Company ”) completed a merger with its wholly-owned subsidiary, MYOS Corporation, and formally assumed the subsidiary’s name by filing Articles of Merger (the “ Articles ”) with the Secretary of State of the State of Nevada. The subsidiary was incorporated entirely for the purpose of effecting the name change and the merger did not affect the Company’s Articles of Incorporation or corporate structure in any other way. In connection with the name change, the Company’s ticker symbol was changed to “MYOS”, effective as of May 21, 2012. A copy of the Articles is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

On May 21, 2012, the Company issued a press release announcing the changes in its name and ticker symbol. A copy of the press release is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit Number		Description

3.1		Articles of Merger filed with the Nevada Secretary of State

99.1		Press release issued by the Company on May 21, 2012

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MYOS CORPORATION

	By:	/s/ Peter Levy
		Name: Peter Levy
		Title: Chief Operating Officer

ROSS MILLER

Secretary of State

204 North Carson Street, Ste 1

Carson City, Nevada 89701-4069

(775) 684-5708

Website: secretaryofstate.biz

Filed in the office of /s/ Ross Miller Ross Miller Secretary of State State of Nevada	Document Number 20120345025-64
	Filing Date and Time 05/15/2012 4:25 PM
	Entity Number E0256042007-3

Articles of Merger

(PURSUANT TO NRS 92A.200)

Page 1

USE BLACK INK ONLY – DO NOT HIGHLIGHT

ABOVE SPACE FOR OFFICE USE ONLY

Articles of Merger

(Pursuant to NRS Chapter 92A)

1) Name and jurisdiction of organization of each constituent entity (NRS 92A.200). If there are more than four merging entities, check box q and attach an 81/2" x11" blank sheet containing the required information for each additional entity.

MYOS CORPORATION
Name of merging entity

Nevada		CORPORATION
Jurisdiction		Entity type*


Name of merging entity


Jurisdiction		Entity type*


Name of merging entity


Jurisdiction		Entity type*


Name of merging entity


Jurisdiction		Entity type*

And,
ATLAS THERAPEUTICS CORPORATION
Name of surviving entity

NEVADA		CORPORATION
Jurisdiction		Entity type*

*corporation, non-profit corporation, limited partnership, limited-liability company or business trust.

ROSS MILLER

Secretary of State

204 North Carson Street, Ste 1

Carson City, Nevada 89701-4069

(775) 684-5708

Website: secretaryofstate.biz

Articles of Merger

(PURSUANT TO NRS 92A.200)

Page 2

USE BLACK INK ONLY – DO NOT HIGHLIGHT

ABOVE SPACE FOR OFFICE USE ONLY

2)	Forwarding address where copies of process may be sent by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger - NRS 92A.1 90):

Attn:

c/o:

3)	(Choose one)

o	The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.200).

x	The undersigned declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180)

Owner's approval (NRS 92A.200) (options a, b, or c must be used, as applicable, for each entity) (if there are more than four merging entities, check box o and attach an 8 112" x 11" blank sheet containing the required information for each additional entity):

(a) Owner's approval was not required from

Name of merging entity, if applicable

And, or;

ATLAS THERAPEUTICS CORPORATION

Name of surviving entitiy, if applicable

ROSS MILLER

Secretary of State

204 North Carson Street, Ste 1

Carson City, Nevada 89701-4069

(775) 684-5708

Website: secretaryofstate.biz

Articles of Merger

(PURSUANT TO NRS 92A.200)

Page 3

USE BLACK INK ONLY – DO NOT HIGHLIGHT

ABOVE SPACE FOR OFFICE USE ONLY

(b) The plan was approved by the required consent of the owners of *:

MYOS CORPORATION

Name of merging entity, if applicable

And, or;

Name of surviving entitiy, if applicable

* Unless otherwise provided in the certificate of trust or governing instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.

ROSS MILLER

Secretary of State

204 North Carson Street, Ste 1

Carson City, Nevada 89701-4069

(775) 684-5708

Website: secretaryofstate.biz

Articles of Merger

(PURSUANT TO NRS 92A.200)

Page 4

USE BLACK INK ONLY – DO NOT HIGHLIGHT

ABOVE SPACE FOR OFFICE USE ONLY

The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.

Name of merging entity, if applicable

And, or;

Name of surviving entitiy, if applicable

ROSS MILLER

Secretary of State

204 North Carson Street, Ste 1

Carson City, Nevada 89701-4069

(775) 684-5708

Website: secretaryofstate.biz

Articles of Merger

(PURSUANT TO NRS 92A.200)

Page 5

USE BLACK INK ONLY – DO NOT HIGHLIGHT

ABOVE SPACE FOR OFFICE USE ONLY

5)	Amendments, if any, to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200)*:

Article I. The name of the corporation shall be MYOS Corporation.

6)	Location of Plan of Merger (check a or b): (a) The entire plan of merger is attached;

o	(a) The entire plan of merger is attached;

Or,

x	(b)The entire plan of merger is on file at the registered office of the surviving corporation, limited-liability company or business trust, or at the records office address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200).

7)	Effective date and time of filing: (optional) (must not be later than 90 days after the certificate is filed)

Date:

Time:

* Amended and restated articles may be attached as an exhibit or integrated into the articles of merger. Please entitle them "Restated" or "Amended and Restated," accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent - Nevada parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the surviving entity may be changed.

ROSS MILLER

Secretary of State

204 North Carson Street, Ste 1

Carson City, Nevada 89701-4069

(775) 684-5708

Website: secretaryofstate.biz

Articles of Merger

(PURSUANT TO NRS 92A.200)

Page 6

USE BLACK INK ONLY – DO NOT HIGHLIGHT

ABOVE SPACE FOR OFFICE USE ONLY

Signatures - Must be signed by: An officer of each Nevada corporation; All general partners of each Nevada limited partnership; All general partners of each Nevada limited-liability limited partnership; A manager of each Nevada limited-liability company with managers or one member if there are no managers; A trustee of each Nevada business trust (NRS 92A.230)*

(if there are more than four merging entitles, check box o and attach an 8 1/2" x 11" blank sheet containing the required information for each additional entity.):

MYOS CORPORATION
Name of merging entity

X	PRESIDENT	05/15/2012
Signature	Title	Date


Name of merging entity

X
Signature	Title	Date


Name of merging entity

X
Signature	Title	Date


Name of merging entity

X
Signature	Title	Date

ATLAS THERAPEUTICS CORPORATION
Name of surviving entity

X	CHIEF OPERATING OFFICER	05/15/2012
Signature	Title	Date

* The articles of merger must be signed by each foreign constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this page or as an attachment, as needed.

Atlas Therapeutics Changes its Name and Ticker Symbol

to MYOS Corporation and “MYOS”; Launches New Corporate Website

Ticker Symbol Change is Effective Today, May 21, Prior to Market Opening

CEDAR KNOLLS, NJ – May 21, 2012 -- Atlas Therapeutics Corporation (OTCBB: ATTH and OTCBB: MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced it has changed its name to MYOS Corporation and its ticker symbol to “MYOS”. The new stock ticker symbol is effective today, May 21, 2012, prior to the opening of the stock market. The Company also announced this morning’s launch of its new, robust corporate website at www.myoscorp.com.

The name change reflects the Company’s transition from a single product company to a company focusing on expanding its muscle biotechnology platform to enable the development of a portfolio of revolutionary muscle health products.

MYOS believes its technology, current and future products and renewed focus represent an important shift to improving health and wellness through sophisticated treatment of muscle biochemistry. The Company believes that this shift will enable it to build a sustainable and profitable business and position itself as a pre-eminent company in the muscle health industry.

About MYOS Corporation

MYOS Corporation is focused on the discovery, development and commercialization of therapeutic products that improve muscle tissue health and performance (www.myoscorp.com).

MYOS is the owner of MYO-T12®, an over-the-counter supplement that is the world's only clinically proven myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12® is manufactured to optimize biological activity and the Company believes it has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12® and to discover why MYOS is known as “The Muscle Company,” TM visit www.MYOT12.com.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Peter Levy, Chief Operating Officer